Larvol Delta - C4-Therapeutics-Presents-Phase-1-Data-at-European-Hematology-Association-EHA-2026-Congress-Highlighting-Cemsidomide-as-a-Potential-BestinClass-IKZF13-Degrader-for-Multiple-Myeloma-in-Heavily-Pretreated-RelapsedRefractory-Population

cemsidomide (CFT7455) - C4 Therap

https://www.globenewswire.com/news-release/2026/06/11/3310320/0/en/c4-therapeutics-presents-phase-1-data-at-european-hematology-association-eha-2026-congress-highlighting-cemsidomide-as-a-potential-best-in-class-ikzf1-3-degrader-for-multiple-myelo.html

Jun 11, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next